- $1.66bn
- $1.37bn
- $184.42m
Stoke Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Stoke Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Stoke Therapeutics Inc Files For Shelf Of Up To 10.8 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Stoke Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Stoke Therapeutics Appoints Thomas Leggett As CFO
Brief: Stoke Therapeutics Appoints Jason Hoitt As Chief Commercial Officer
U.S. RESEARCH ROUNDUP- Ally Financial, GE Vernova, Navient
Stoke Therapeutics eases after upsized $125 mln equity raise
Brief: Stoke Therapeutics Announces Pricing Of Upsized $125 Million Public Offering
U.S. STOCKS ON THE MOVE-Netflix, Reddit, Stoke Therapeutics
U.S. STOCKS ON THE MOVE-Spirit Airlines, Cintas, Reddit
Stoke Therapeutics surges again after stock offering launch
Brief: Stoke Therapeutics Announces Proposed Public Offering
U.S. STOCKS ON THE MOVE-Nuvation Bio, Seagate, AppFolio
U.S. STOCKS ON THE MOVE-Reddit, CONSOL Energy, Nuvation Bio
U.S. STOCKS ON THE MOVE-Gold miners , Alibaba, McCormick